ONSD Trajectory in Rebound ICH (ONSD/ INH)
Optic Nerve Sheath Diameter Trajectory During Osmotherapy Weaning as a Predictor of Rebound Intracranial Hypertension in Traumatic Brain Injury
The goal of this prospective observational study is to determine whether the trajectory of optic nerve sheath diameter (ONSD) after osmotherapy weaning can predict rebound intracranial hypertension in adult patients with traumatic brain injury requiring osmotherapy for elevated intracranial pressure. The main questions it aims to answer are:
Does the trajectory of ONSD during osmotherapy weaning predict the development of rebound intracranial hypertension? What is the diagnostic accuracy of serial ONSD measurements for the early detection of rebound intracranial hypertension? Researchers will compare patients who develop rebound intracranial hypertension with those who do not to determine whether changes in ONSD trajectory differ significantly between the two groups.
Participants will:
Undergo serial bedside ocular ultrasound examinations for ONSD measurement at predefined time points after osmotherapy weaning.
Receive standard clinical management for traumatic brain injury according to institutional protocols; no additional therapeutic intervention will be administered.
Undergo routine neurological assessments, laboratory investigations, and neuroimaging as clinically indicated.
Be followed for the occurrence of rebound intracranial hypertension and relevant clinical outcomes during their ICU stay
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Cerebral edema and elevated intracranial pressure (ICP) are common secondary complications that require prompt management to prevent further neurological injury. Osmotherapy with hypertonic saline or mannitol is routinely used to reduce ICP; however, withdrawal or weaning of osmotherapy may be associated with rebound intracranial hypertension, which can worsen neurological outcomes if not recognized early.
Optic nerve sheath diameter (ONSD), measured by bedside ocular ultrasonography, is a non-invasive surrogate marker of raised intracranial pressure. Although ONSD has been shown to correlate with ICP in several clinical settings, the predictive value of serial ONSD measurements during osmotherapy weaning for identifying rebound intracranial hypertension has not been adequately investigated.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Mostafa Mohamed Sakr, Critical care MSC
- Telefonní číslo: +201069610038 +201002338765
- E-mail: sasasakr6@gmail.com
Studijní místa
-
-
Qalyobia
-
Banhā, Qalyobia, Egypt
- Benha university hospital
-
Kontakt:
- Mostafa M Abdelgwad, MSC
- Telefonní číslo: +201002338765
- E-mail: sasasakr6@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Adults (≥18 years) with blunt traumatic brain injury admission GCS ≤12
- (or GCS 13-15 with CT signs of elevated ICP including midline shift ≥5 mm, effaced cisterns, or significant cerebral edema)
- clinical decision to initiate 20% mannitol osmotherapy
Exclusion Criteria:
- Ocular conditions precluding ONSD measurement (glaucoma, prior ocular surgery,
- globe or optic nerve trauma,
- periorbital edema, orbital masses, optic nerve sheath cysts);
- planned decompressive surgery or evacuation of mass lesion within 48 hours; limitation of life-sustaining therapy; pregnancy; contraindications to mannitol (baseline sodium >155 mEq/L, osmolality >320 mOsm/kg, eGFR <30 mL/min); penetrating TBI; or concurrent spinal cord injury with shock.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Traumatic Brain Injury Patients Undergoing Osmotherapy Weaning
Adult patients with traumatic brain injury receiving osmotherapy for intracranial hypertension who undergo protocol-defined osmotherapy weaning.
Participants will undergo serial optic nerve sheath diameter (ONSD) measurements before and after osmotherapy reduction or discontinuation and will be followed prospectively for the development of rebound intracranial hypertension and related clinical outcomes.
|
Serial ultrasonographic measurement of optic nerve sheath diameter (ONSD) will be performed bilaterally using a standardized transorbital ultrasound technique immediately before osmotherapy reduction or discontinuation (baseline) and at 4, 6, 12, and 24 hours after weaning.
Additional measurements may be obtained if clinical deterioration suggestive of rebound intracranial hypertension occurs.
ONSD measurements are performed for observational purposes only and will not influence routine clinical management.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Prediction of rebound intracranial hypertension using serial ONSD measurements
Časové okno: Within 24 hours after osmotherapy reduction or discontinuation
|
Within 24 hours after osmotherapy reduction or discontinuation
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mortality
Časové okno: From ICU admission until ICU discharge or death, assessed for up to 28 days.
|
Death from any cause occurring during the patient's ICU stay following traumatic brain injury and during the study observation period.
|
From ICU admission until ICU discharge or death, assessed for up to 28 days.
|
|
2. Length of ICU Stay:
Časové okno: From ICU admission until ICU discharge or death, assessed for up to 28 days.
|
The total duration of ICU admission measured in days from ICU admission until ICU discharge or death.
|
From ICU admission until ICU discharge or death, assessed for up to 28 days.
|
|
Need for rescue ICP therapy:
Časové okno: Within 48 hours after osmotherapy weaning.
|
Requirement for additional ICP-lowering interventions beyond restarting osmotherapy due to suspected or confirmed rebound intracranial hypertension.
Rescue therapies include: (a) barbiturate infusion (thiopental or pentobarbital), (b) therapeutic hypothermia (target temperature ≤35°C), or (c) controlled hyperventilation (PaCO₂ <30 mmH
|
Within 48 hours after osmotherapy weaning.
|
|
Glasgow Coma Scale trajectory post-weaning
Časové okno: Measured at baseline (immediately before osmotherapy weaning), then at 4, 6, 12, and 24 hours after weaning (aligned with ONSD measurement time points). The primary analysis will use change in GCS from baseline to 24 hours as a continuous variable.
|
Neurological status assessed using the Glasgow Coma Scale (GCS).
The GCS total score ranges from 3 to 15, with higher scores indicating better neurological function.
A decrease of ≥2 points from the baseline GCS score after osmotherapy discontinuation is considered neurological deterioration suggestive of rebound intracranial hypertension.
|
Measured at baseline (immediately before osmotherapy weaning), then at 4, 6, 12, and 24 hours after weaning (aligned with ONSD measurement time points). The primary analysis will use change in GCS from baseline to 24 hours as a continuous variable.
|
|
Time to rebound intracranial hypertension
Časové okno: Assessed continuously during the first 48 hours after osmotherapy weaning. For patients who do not develop rebound, time will be censored at 48 hours.
|
The interval (in hours) from complete osmotherapy discontinuation (T0) to the first documented episode of rebound intracranial hypertension.
Rebound is identified by either: (a) decline in GCS of ≥2 points from baseline not attributable to other causes, or (b) worsening on brain imaging showing increased cerebral edema or mass effect.
|
Assessed continuously during the first 48 hours after osmotherapy weaning. For patients who do not develop rebound, time will be censored at 48 hours.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- MD_6.5.2026
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Traumatické zranění mozku
-
Neurolutions, Inc.Zatím nenabírámeMrtvice | Hemiparéza po mrtvici | Rozhraní Brain Computer
-
The Hong Kong Polytechnic UniversityDokončenoMrtvice | Rozhraní Brain ComputerHongkong
-
Uludag UniversityDokončenoPorucha pozornosti s hyperaktivitou (ADHD) | Rozhraní Brain ComputerTurecko (Türkiye)
-
Wright State UniversityAktivní, ne náborBolest hlavy | Bolest hlavy vyvolaná chladem | Brain Freeze | Cephalgie vyvolaná chlademSpojené státy
-
Neurolutions, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development...DokončenoMrtvice | Hemiparéza | Spasticita jako pokračování mrtvice | Rozhraní Brain ComputerSpojené státy